Turnover rates of the apolipoprotein of low density lipoproteins (apoLDL) and cholesterol balance were determined in six obese men and six control men. The two groups were of similar age and matched for apoLDL concentrations. Levels of plasma total cholesterol in obese patients (209 ± 14 SEumg/dl) were similar to controls (225 ± 17 mg/dl). LDL-cholesterol was numerically but not statistically lower in obese subjects (111 ± 18 mg/dl) compared to controls (145 ± 13 mg/dl). Synthetic rates of apoLDL in contrast were higher in obese patients (1450 mg/day) than in controls (934 mg/day) (p < 0.002). Three factors could explain the similar concentrations of LDLcholesterol in obese and control subjects, despite overproduction of apoLDL in the obese. First, LDL was diluted into a larger plasma pool in obese patients; second, fractional catabolic rates of apoLDL were somewhat greater in obese men than in controls; and third, obese patients had higher ratios of protein-to-cholesterol in LDL. The production of apoLDL for all patients was not correlated with total body synthesis of cholesterol. The major finding of this study was that obese patients have increased turnover of apoLDL, not necessarily reflected by high concentrations of LDL-cholesterol. This high turnover rate itself may raise the risk for coronary heart disease in obese patients. (Arteriosclerosis 3
T he obese state is known to alter lipid metabolism in man. Synthetic rates of cholesterol and bile acid are increased in obese subjects, 1 " 4 as are production rates of very low density lipoprotein-triglycerides (VLDL-TG). 5 " 7 Since VLDL is a precursor of low density lipoproteins (LDL), 89 overproduction of VLDL might be expected to increase LDL. Many obese subjects, however, have normal concentrations of plasma cholesterol and LDL-cholesterol. 10 To resolve this seeming paradox, we undertook a study of LDL metabolism in a group of obese subjects who had relatively normal levels of plasma lipids. The study was designed primarily to determine whether metabolism of apolipoprotein B of LDL (apoLDL) is abnormal in obese patients who have normal concentrations of apoprotein B and cholesterol in the LDL fraction. The results showed that production and clearance rates of apoLDL can be altered significantly by obesity even in the presence of normal plasma concentrations of lipids and lipoproteins.
Methods

Patients
Six obese men and six healthy male controls were studied (Table 1) . At the time of study the obese patients were 54.1 ± (SEM) years old (range 50 to 57 years), and their mean body weight was 114 ± 7 kg. Each subject had a weight exceeding 130% of their ideal body weight according to the Metropolitan Life Insurance tables (assuming a medium body frame). 11 The mean weight of the patients was 171 % ± 13% of the ideal weight. None had xanthomata, xanthelasma, or fasting or 2-hour postprandial hyperglycemia. 12 None had a history of hypertension, myocardial infarction, or hepatic or renal disease. One patient (No. 3) had a history of gout treated with allopurinol. The patients' plasma cholesterol and triglyceride (TG) levels were measured on their home diet before the study (Table 1) . Five had a plasma cholesterol level below the 95th percentile for the corresponding age and sex group according to the data of the Lipid Research Clinics Program Prevalence Study. 13 ' u None of the patients were on or had been on any special diet or lipid-lowering drugs.
The six control subjects had no history of coronary heart disease, hypertension, diabetes mellitus, or hepatic or renal disease. None had xanthomata, xanthelasma, or fasting or 2-hour postprandial hyperglycemia. 12 Their ages averaged 60 ± 2 years (range 54 to 68 years). Their body weights averaged 74 ± 5 kg, which was 106 ± 6% of their ideal weight. None exceeded 118% of the ideal weight. Also, none were on or had been on lipid-lowering diets or drugs. Plasma lipid levels on the control subjects' home diets were tested before the study. The values fell below the 95th percentile for the corresponding age and sex group in all except one subject (No. 11), whose plasma cholesterol was slightly above the 95th percentile. 13 ' 14 The investigations were approved by the Institutional Review Boards of San Diego Veterans Administration Medical Center and University of California, San Diego. All patients gave informed consent. Studies were carried out in the Special Diagnostic and Treatment Unit (metabolic unit) at the Veterans Administration Medical Center, San Diego, California.
Experimental Design
Patients underwent measurements of turnover of LDL-protein (apoLDL). In addition, the cholesterol balance was determined in four obese subjects and in all controls. Patients and controls were hospitalized for 5 to 6 weeks. The patients were on the same repetitive metabolic diet throughout the study. Their plasma lipid and lipoproteins levels were estimated twice weekly.
Diets
The metabolic diet consisted of mixed solid food and liquid formula containing 40% calories as fat. The basic composition and pattern of this diet has been described previously in detail. 15 The patients were given three liquid meals and one solid food meal per day. Calories were divided approximately equally between the feedings. Liquid feedings were given at 8:30 a.m., 1:00 p.m., and 7:00 p.m., and they contained 15% of calories as milk protein, 45% as dextrose, and 40% as fat, mostly in the form of lard. These diets were prepared by Hospital Diet Products, Organon Corporation, Buena Park, California (Courtesy of Fred Teixeira). One solid food meal was given at 11:00 a.m., and it contained dry cereal (corn flakes), nonfat bread, skim milk, added fat, and sugar for coffee. Fat comprised approximately 40% of calories in the solid food meals. Cholesterol intakes ranged between 98 and 234 mg/day. Vitamin and mineral supplements were given daily. Each patient was weighed daily and caloric intake was adjusted to maintain total body weight at a constant level throughout the study.
Plasma Llplds and Lipoproteins
Blood for plasma lipid and lipoprotein quantification was obtained twice weekly after a 12-hour fast. Total cholesterol and TG were determined on a Technicon Auto-Analyzer (Model II, Technicon Instruments Corporation, Tarrytown, New York). 1617 Concentrations of cholesterol and TG in very low density lipoprotein (VLDL), low density lipoprotein (LDL), and high density lipoprotein (HDL) were estimated as described in the Lipid Research Clinics Manual of Laboratory Operations. 18
Lipoprotein Turnover Studies
Measurements of turnover of apoLDL were performed as described previously. 1920 After the patients had been on the metabolic diet described above for 10 days to 2 weeks and when the total cholesterol and LDL-cholesterol were constant, plasmapheresis was carried out. LDL (d = 1.025-1.060 g/ml) was isolated from each patient, and the protein moiety was labeled with 12S I by the iodinemonochloride method of McFariane 21 as modified by Bilheimer et al. 8 Unbound 125 I was removed by dialysis and the labeled LDL was diluted with 5% human serum albumin and sterilized by passage through a 0.22/AM Millipore filter. The degree of lipid labeling was determined by extraction of the labeled LDL with a chloroforrn:methanol solvent (2:1, vol/vol) using the method Folch et al. 22 The organic phase was evaporated to dryness, and the residual lipid was counted in dry tubes. The mean percentage of counts in the lipid moiety was 3.7% (0.8% to 6.8%). The mean amount of unbound iodine after dialysis was checked by thin layer chromatography on Gelman ITLC-SG sheets (Gelman Instrument Company, Ann Arbor, Michigan) using 20% trichloroacetic acid containing 0.125% sodium metabisulfite as a chromatography system. The number of counts at the solvent front compared to the total counts present was taken to represent the percentage of 125 I not bound to LDL protein. This amount averaged 0.36% (0.11% to 0.89%). The labeled LDL was injected intravenously; it contained 50 to 70 /xCi of radioactivity and 2 to 10 mg of protein. Blood samples were collected at 5,10,15,20, 30, and 60 minutes; 3,6,9, 12, 24, 36, and 48 hours; and daily (fasting) thereafter for 14 to 21 days. Determinations of radioactivity and concentrations of total cholesterol and TG were made on each plasma sample. Lipoprotein lipid and protein quantification was done biweekly throughout the study.
Urine specimens were collected in bottles containing an alkaline preservative 23 and were pooled during the following time intervals after the intravenous injection of 125 I-LDL: "0 time" to 1 hour, 1 to 3, 3 to 6, 6 to 12, and 12 to 24 hours and for every 24-hour period thereafter. Values for urinary radioactivity were normalized to a constant creatinine excretion. All radioactivity was determined in a Packard Model 5820 automatic gamma scintillation spectrometer (Packard Instrument Company, Downers Grove, Illinois). The patients received 0.5 to 0.9 gms of Kl orally in divided doses each day to suppress 125 I uptake by the thyroid. The fractional catabolic rate (FCR) and synthesis rate for apoLDL were determined as previously described. 19 ' x Briefly, two exponential components of the die-away curve of plasma radioactivity were fit with the 2-pool Matthews model; 24 the data were used to calculate an FCR for plasma apoLDL The FCR was measured independently by relating the daily urinary excretion rate of 12S I radioactivity to the 12S I radioactivity in plasma (U/P ratio) as described previously. 20 The synthetic rate for apoLDL was calculated as follows: apoLDL synthesis = (plasma apoLDL concentration) x (plasma volume) x (FCR). Plasma volume was calculated by the isotope-dilution technique from the known injected dose and the intercept of the calculated 2-exponential curve. The concentration of apoLDL was calculated from the mean of the 4 to 6 measured values for LDL-cholesterol and the 4 to 6 measured ratios of protein:cholesterol in each patient's LDL. These measurements were done biweekly throughout the study. LDL protein was determined by a modified method of Lowry et al. 25 as described by Sata et al. 26 Since this study compared synthesis rates of apoLDL between patients with marked obesity and those of normal body weight, we considered how best to normalize the results so that a meaningful comparison could be made. We decided that the best comparison is total transport rates in the two groups. Previously, we also expressed transport rates as milligrams per kilogram of ideal weight. 520 This expression essentially normalizes for height. Since there was no great discrepancy between the average heights of the two groups, this normalization added little to a comparison of total transport rates. Data normalized per kilogram of total body weight and per square meter of surface area also are given. In our view, both, and particularly the former, data may be misleading in obese subjects; normalization per kilogram of total body weight can reduce estimated transport rates to inordinately low values and fail to reflect absolute rates. In other words, dividing transport rates by a large mass of adipose tissue could obscure real increases in the production of apoLDL.
Cholesterol Balance Studies
Estimations of cholesterol balance were made as described earlier. 27 -29 Stools were collected throughout the study period and either combined into one representative pool for all the samples or combined into 7-day pools. Fecal neutral and acidic steroids were isolated separately, and their masses were determined by gas-liquid chromatography (GLC). 2728 GLC analysis of neutral steroids distinguishes between cholesterol and plant sterols and their steroid conversion products. Analyses were carried out entirely by chemical procedures. To correct for losses of neutral steroids, beta-sitosterol was given as capsules (225 mg twice daily), 29 and excretions of acidic steroids were corrected for variations in fecal flow by use of chromic oxide. 30
Statistical Analysis
The differences between the parameters of the two groups were compared by Student's t test. Table 2 gives the concentrations of plasma total cholesterol and TG; also shown are the cholesterol and TG in each of the lipoproteins, VLDL, LDL, and HDL. Similar values for the plasma total cholesterol and TG were found on the home diet (Table 1 ) and the hospital diet ( Table 2) . One obese patient (No. 6) had slightly elevated total and LDL-cholesterol, but the overall values for plasma lipid and lipoproteins of obese subjects fell below the 95th percentile for the general U.S. population. 13 ' 14 The same was true for all controls except Subject 12, whose total cholesterol and LDL-cholesterol were slightly elevated. 1314 There were no differences between the two groups in the plasma concentrations of total cholesterol, total TG, or LDL-cholesterol. Obese subjects had higher VLDL-cholesterol (56 ± 4 vs 28 ± 5 mg/dl, p < 0.005) and lower HDL-TG than controls (16 ± 1.5 vs 25 ± 2 mg/dl, p < 0.05). Table 3 presents kinetic parameters for 12S I-apoLDL in obese patients and control subjects. The concentrations of apoLDL were similar for the two groups. The plasma volumes were higher in the obese subjects, but their total mass of apo LDL was not significantly increased. Obese patients had high-er protein:cholesterol ratios in LDL than controls. The FCRs of apo LDL appeared to be slightly higher in obese subjects. Absolute rates of apoLDL synthesis in the obese patients were distinctly higher than in the controls.
Results
Plasma Llplds and Llpoprotelns
Apo LDL Kinetics
In Table 4 synthesis rates of apoLDL are expressed in four ways, as absolute rates, and as rates normalized to ideal body weight, total body weight, and square meter of body surface. Normalization to ideal weight (which essentially normalizes for height) showed about the same differences as absolute rates. The mean values expressed per square meter were marginally different between the two groups, and no difference was evident when the results were normalized to kilograms of total body weight.
Cholesterol Balance
Measurements of cholesterol balance were carried out in four obese subjects and in all the controls ( Table 5 ). The values for total neutral steroids, total steroids, and cholesterol balance were numerically higher in obese subjects than in controls, but the differences were not statistically significant. Acidic steroid outputs, however, were significantly higher in obese patients. For all patients, neither cholesterol balance nor excretion of acidic steroids (bile acids) were correlated with apoLDL synthesis (r = 0.14, r = 0.40, respectively) or with FCR of apoLDL (r = 0.07, r = 0.15, respectively). 
Discussion
ApoLDL Synthesis
A primary aim of this study was to determine whether obese subjects have alterations in their LDL metabolism even when concentrations of apoLDL and LDL-cholesterol are not abnormally high. The data showed that LDL turnover was abnormally high in obese patients. Synthesis of apoLDL in obese subjects averaged 55% higher than in nonobese controls. The abnormality was obscured when the data were expressed per kilogram of absolute body weight. We contend, however, that the latter normalization does not give a true picture of LDL metabolism in obese patients.
How can we account for overproduction of apoLDL in the obese state? Several possibilities must be considered. First, increased synthesis of triglycerides could stimulate apolipoprotein B (apo B) production. Many obese patients overproduce VLDL-TG. 5 -7 If synthesis of apo B and VLDL-TG in the liver are linked, the excess formation of VLDL-TG could cause increased outputs of VLDL-apo B. This, in turn, might cause a high conversion of VLDL-apo B to LDL-apo B, a change that would be recognized as elevated synthesis of apoLDL.
Apo B production also could be tied to cholesterol synthesis. Obese patients are known to synthesize more cholesterol than normal; 1 " 531 this, too, could stimulate production of apo B. One result might be an increased "direct" synthesis of LDL. Our recent data have shown that individuals with total plasma cholesterol ranging from high-normal to mildly-elevated frequently derive a considerable portion of their apoLDL independently of VLDL, presumably by direct synthesis of LDL. 32 Although the synthesis rates of cholesterol in current patients were not correlated with the production of apoLDL, the fact remains that obese patients overproduce both cholesterol and apoLDL; studies on more patients therefore might reveal a connection. We also must consider the possibility that the stimulus for the overproduction of apo B in obesity is independent of lipids. An excessive intake of total calories, or the hormonal consequences of increased calories, could directly promote the synthesis of apo B. The lipoprotein species with which an excess apo B enters the plasma may depend on the coincidental state of lipid metabolism. If hepatic TG synthesis is high, most apo B probably would be incorporated into VLDL. If it is relatively low, VLDLindependent secretion of LDL may predominate.
Another mechanism contributing to increased formation of apoLDL could be a high fractional conversion of VLDL to LDL. In nonobese, normolipidemic patients, most VLDL appears to be converted to LDL. 89 In hypertriglyceridemic patients, on the other hand, the fractional conversion may be as low as 50 o /o 33-38 VLDL particles not transformed into LDL presumably are removed as VLDL remnants by the liver. In obese, normotriglyceridemic patients this alternate path may be small; despite their overproduction of VLDL-TG, obese patients may resemble normal subjects more than hypertriglyceridemic patients by transforming a larger portion of VLDL to LDL.
Regulation of ApoLDL and LDL-Cholesterol Concentrations
Our finding of overproduction of apoLDL with normal concentrations of LDL-cholesterol presents a paradox. This is especially so because of our recent report claiming that concentrations of LDL in nonobese subjects are determined primarily by synthetic rates of apoLDL. 20 Previous subjects with higher synthetic rates generally had higher levels of apoLDL and LDL-cholesterol. The absence of this relationship in our obese subjects, therefore, requires an explanation.
One factor preventing a rise in LDL despite its overproduction was a high plasma volume. Total plasma volumes were greater in obese subjects than in controls; the dilution of the total mass of plasma apoLDL into a larger volume lowered the concentration. Another factor was a relatively high FCR of apoLDL. The FCR averaged 24% greater in obese subjects. An increased FCR might have several causes. One could be an unusually large mass of tissue removing LDL from the circulation. In markedly overweight patients, the absolute numbers of adipocytes are increased. Adipose tissue cells have the capacity to degrade LDL in vitro. 37 Presumably, the same potential exists in vivo; if so, increased numbers of adipocytes should dispose of appreciable amounts of LDL. This, however, is not the only possible mechanism for the enhanced clearance of LDL. A high intake of total calories could stimulate catabolism of LDL elsewhere than adipose tissue. The overall metabolism of lipids and lipoproteins may be increased in obesity as reflected by high synthesis rates of cholesterol and VLDL-TG.^ If production of lipids is stimulated in the obese state, catabolism also may be promoted; one manifestation of the lat-ter could be a greater uptake and degradation of LDL by the liver. One factor mediating or promoting the clearance of LDL in the obese state may be hyperinsulinemia. Insulin can stimulate uptake and degradation of LDL by cultured human fibroblasts. 38 Treatment of insulin-deficient patients with insulin also lowers LDL. 39 The high concentrations of plasma insulin found in obesity thus could promote catabolism of LDL; the result would be less of a rise in LDL than otherwise expected with overproduction of apoLDL.
Another finding in our obese patients was a significantly elevated ratio of protein cholesterol in LDL. This higher ratio could have several origins. Overproduction of apo B might enrich LDL with this apoprotein. Alternatively, in the conversion of VLDL to LDL unusually large amounts of cholesterol could have been lost. A more likely mechanism, however, is an increased FCR of LDL. As LDL circulate in plasma, they acquire cholesterol ester, either directly or indirectly, through the action of lecithin-cholesterol acyltransferase (LCAT). If the residence time of LDL is relatively short, as in obese patients, less time is available for the accumulation of cholesterol ester; a rise in the protein cholesterol ratio in LDL should be the result. In a recent study, we reported a significant negative correlation between the FCR of LDL and its protein cholesterol ratio. 20 Relatively low concentrations of LDL-cholesterol in obese subjects thus may be related doubly to an increased FCR, first to rapid clearance of LDL from plasma, and second to higher protein cholesterol ratios.
Obesity, ApoLDL Metabolism, and Coronary Heart Disease
If obesity promotes the development of atherosclerosis, it probably acts through other risk factors. It raises the blood pressure, increases VLDL, 5 and lowers HDL. 9 These changes may impart an increased risk for coronary heart disease (CHD). An elevation of LDL-cholesterol also has been attributed to obesity, but we have not been able to confirm this effect. 9 All the atherogenic effects of obesity, however, may not be through known risk factors; several epidemiological studies suggest that excess body weight is an "independent" risk factor. 40 " 45 The results reported here may partially account for this claim. Art increased turnover of apoLDL itself may be a risk factor for CHD. In a recent study 46 we measured the turnover of apoLDL in a group of patients with documented CHD but with normal lipid levels. They were compared to a similar normolipidemic group without CHD. Patients with CHD had significantly higher turnover rates of apoLDL. Although these patients were not obese, they had almost identical values for synthesis apoLDL as the obese patients studied here. The production of apoLDL in the CHD patients averaged 21.5 ± 1.9 mg/day/kglW compared to 21.3 ± 2.4 mg/day/kg IW for the obese group in the current study. An excess synthesis of apoLDL, independent of LDL concentrations, thus could be another risk factor for CHD. If so, obesity may be more important for CHD risk than previously recognized; it probably is the most common cause of overproduction of LDL.
The high ratios of proteincholesterol in LDL also may be relevant. Available evidence suggests that all LDL particles have the same content of apoB. Concentrations of LDL-apoB thus should reflect LDL particle number. The obese patients of this study had 30% more apoLDL per mg LDL-cholesterol than controls. At a given concentration of LDL-cholesterol, therefore, obese patients should have approximately 30% more LDL particles than nonobese subjects. This difference might put obese patients in a higher category of risk than revealed by cholesterol levels alone.
